

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM650975

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Release of Security Interest in Intellectual Property		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
GLAS Trust Company LLC		06/01/2021	Limited Liability Company: NEW HAMPSHIRE
RECEIVING PARTY DATA			
Name:	Concordia Laboratories, Inc.		
Street Address:	8-10 Avenue de la Gare		
City:	Luxembourg		
State/Country:	LUXEMBOURG		
Postal Code:	L-1610		
Entity Type:	Corporation: LUXEMBOURG		
Name:	Concordia Pharmaceuticals Inc.		
Street Address:	8-10 Avenue de la Gare		
City:	Luxembourg		
State/Country:	LUXEMBOURG		
Postal Code:	L-1610		
Entity Type:	Corporation: LUXEMBOURG		
Name:	Amdipharm Limited		
Street Address:	Suite 17 Northwood House, Northwood, Santry		
City:	Dublin 9		
State/Country:	IRELAND		
Entity Type:	Limited: IRELAND		
PROPERTY NUMBERS Total: 18			
Property Type	Number	Word Mark	
Registration Number:	1949186	NILANDRON	
Registration Number:	1470405	PLAQUENIL	
Registration Number:	712043	PLAQUENIL	
Registration Number:	562377	PLAQUENIL	
Registration Number:	2679884	UROXATRAL	
Registration Number:	0667320	KAYEXALATE	
Registration Number:	4158771	DUTOPROL	
Registration Number:	785081	DYRENIUM	
TRADEMARK			

CH \$465.00 1949186

Property Type	Number	Word Mark
Registration Number:	548626	DIBENZYLINE
Registration Number:	4365005	KAPVAY
Registration Number:	2185127	ORAPRED
Registration Number:	3248392	ORAPRED ODT
Registration Number:	338733	DONNATAL
Registration Number:	5472525	CONCORDIA RX
Registration Number:	1367281	PHOTOFRIN
Registration Number:	2055737	OPTIGUIDE
Registration Number:	2909621	AMDIPHARM
Registration Number:	0798943	

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2128192511
Email: iprecordations@whitecase.com
Correspondent Name: Kate Andes
Address Line 1: 1221 Avenue of the Americas
Address Line 4: New York, NEW YORK 10020

ATTORNEY DOCKET NUMBER:	4485470-0005-CM65
NAME OF SUBMITTER:	Kate Andes
SIGNATURE:	/Kate Andes/
DATE SIGNED:	06/01/2021

Total Attachments: 6
source=Advanz - Release of Security Interest in Intellectual Property Collateral (Executed)#page1.tif
source=Advanz - Release of Security Interest in Intellectual Property Collateral (Executed)#page2.tif
source=Advanz - Release of Security Interest in Intellectual Property Collateral (Executed)#page3.tif
source=Advanz - Release of Security Interest in Intellectual Property Collateral (Executed)#page4.tif
source=Advanz - Release of Security Interest in Intellectual Property Collateral (Executed)#page5.tif
source=Advanz - Release of Security Interest in Intellectual Property Collateral (Executed)#page6.tif

**RELEASE OF SECURITY INTEREST IN
INTELLECTUAL PROPERTY**

This **RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY** (this “Release”), dated as of June 1, 2021, is made by GLAS Trust Company LLC, as Collateral Trustee (the “Collateral Trustee”), pursuant to that certain Credit and Guaranty Agreement, dated as of September 6, 2018 (as amended, supplemented, extended, restated, or otherwise modified from time to time prior to the date hereof, the “Credit Agreement”) and that certain Pledge and Security Agreement, dated as of September 6, 2018 (as amended, restated, supplemented or otherwise modified from time to time, the “Security Agreement”). Capitalized terms used in this Release and not otherwise defined have the respective meanings assigned thereto in the Security Agreement.

WITNESSETH

WHEREAS, Concordia Laboratories Inc., Concordia Pharmaceuticals Inc. and Amdipharm Limited (collectively, the “Grantors”) are party to the Credit Agreement and the Security Agreement;

WHEREAS, pursuant to the Credit Agreement and the Security Agreement, the Grantors executed and delivered to the Collateral Trustee that certain Intellectual Property Security Agreement, dated as of September 6, 2018, which was recorded with the United States Patent and Trademark Office on September 6, 2021 at Reel/Frame 6431/0652 and 047028/0553, (the “IP Security Agreement”), pursuant to which each of the Grantors granted to the Collateral Trustee a security interest in their Intellectual Property Collateral (as defined in the IP Security Agreement);

WHEREAS, as of the date hereof, all of the obligations secured by the security interest granted under the IP Security Agreement have been paid, performed, satisfied and discharged in full and, in connection therewith, the Grantors have requested that the Collateral Trustee release their respective security interests in all of its right, title and interest in and to the Intellectual Property Collateral (as defined in the IP Security Agreement).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Collateral Trustee hereby agrees as follows:

1. The Collateral Trustee hereby DISCHARGES, TERMINATES and RELEASES its security interest in all right, title and interest in and to the Intellectual Property Collateral (as defined in the IP Security Agreement), including the patents set forth in Schedule I attached hereto and incorporated herein by reference and the trademarks set forth in Schedule II attached hereto and incorporated herein by reference, including the goodwill symbolized thereby. The undersigned hereby transfers and assigns to the Grantors any and all right, title and interest that the Collateral Trustee may have obtained in, to and under the Intellectual Property Collateral (as defined in the IP Security Agreement). The Collateral Trustee hereby waives and relinquishes all its rights, powers, privileges, and remedies with respect to the Grantors and their successors and assigns from all covenants, obligations, liabilities and warranties in association with the Intellectual Property Collateral.

2. The Collateral Trustee authorizes and requests that the United States Patent and Trademark Office and any other applicable government office record this Release.

3. The Collateral Trustee agrees to promptly file this release with the United States Patent and Trademark office and take all further actions and provide to the Grantors and their successors, assigns

and legal representatives all such cooperation and assistance, including, without limitation, the execution and delivery of any and all further documents or other instruments, in each case as the Grantors and their successors, assigns and legal representatives may reasonably request in order to confirm, effectuate or record the release of the security interest contemplated hereby.

4. This Release shall be governed by, and construed in accordance with, the laws of the State of New York.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Collateral Trustee has caused this Release to be duly executed and delivered as of the date first written above.

GLAS TRUST COMPANY LLC,
as Collateral Trustee

By: 

Name:

Yana Kistenko

Title:

Vice President

[Signature Page to Platinum - Release of Security Interest in IP]

TRADEMARK
REEL: 007312 FRAME: 0449

SCHEDULE I
to
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

U.S. PATENTS

a **Concordia Laboratories Inc.**

Country / Region	Patent Name / Application	Application Filing Date, Date Issued/ Published	Application Number, Registration / Publication Number	Owner
United States	Lighting Systems and Methods of Using Lighting Systems for In Vitro Potency for Photofin	November 29, 2012 June 21, 2016	13/689,490/9,371,555	Concordia Laboratories Inc.
United States	Lighting Systems and Methods of Using Lighting Systems for In Vitro Potency for Photofin	June 6, 2016	15/175,013	Concordia Laboratories Inc.

SCHEDULE II
to
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

U.S. TRADEMARKS

a. Concordia Pharmaceuticals Inc.

Country / Region	Trademark	Application No.	Registration No.	Date of Registration	Owner
United States	NILANDRON	74/646,174	1949186	January 16, 1996	Concordia Pharmaceuticals Inc.
United States	PLAQUENIL	73/662,985	1470405	December 29, 1987	Concordia Pharmaceuticals Inc.
United States	PLAQUENIL	72/102433	712043	March 7, 1961	Concordia Pharmaceuticals Inc.
United States	PLAQUENIL	71/618068	562377	July 29, 1952	Concordia Pharmaceuticals Inc.
United States	UROXATRAL	76/233890	2679884	January 28, 2003	Concordia Pharmaceuticals Inc.
United States	KAYEXALATE	72/044216	0667320	September 23, 1958	Concordia Pharmaceuticals Inc.
United States	DUT OPROL	85/266138	4158771	June 12, 2012	Concordia Pharmaceuticals Inc.
United States	DYRENIUM	72/193818	785081	February 16, 1965	Concordia Pharmaceuticals Inc.
United States	DIBENZYLIN	71/586367	548626	September 25, 1951	Concordia Pharmaceuticals Inc.
United States	KAPVAY	77/864,611	4,365,005	July 9, 2013	Concordia Pharmaceuticals Inc.
United States	ORAPRED	75/284,813	2,185,127	August 25, 1998	Concordia Pharmaceuticals Inc.
United States	ORAPREDODT	78/642,154	3,248,392	May 29, 2007	Concordia Pharmaceuticals Inc.
United States	DONNATAL	71/377,644	338733	September 15, 1936	Concordia Pharmaceuticals Inc.
United States	CONCORDIA RX(Stylized)	87140304	5472525	May 22, 2018	Concordia Pharmaceuticals Inc., S.à.r.L

b. Concordia Laboratories Inc.

Country / Region	Trademark	Application No.	Registration No.	Date of Registration	Owner
United States	PHOTOFRIN	73-437,839	1,367,281	October 29, 1985	Concordia Laboratories Inc.
United States	OPTIGUIDE	74-502,189	2055737	April 22, 1997	Concordia Laboratories Inc.

c Amdi pharm Limited

Country / Region	Trademark	Application No.	Registration No.	Date of Registra- tion	Registered Owner
United States	AMDIPHARM	76502173	2909621	December 14, 2004	Amdipharm Limited
United States	AMDIPHARM	0798943	4100710	February 21, 2012	Amdipharm Limited